Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75575
UPID:
RPC9_HUMAN
Alternative names:
Calcitonin gene-related peptide-receptor component protein
Alternative UPACC:
O75575; A8MUZ4; A8MW23; B2R4H4; B4E198; Q3KRA3; Q5HYF1; Q8IXL4
Background:
DNA-directed RNA polymerase III subunit RPC9, also known as Calcitonin gene-related peptide-receptor component protein, plays a pivotal role in the transcription of DNA into RNA, focusing on small RNAs like 5S rRNA and tRNAs. It is crucial in the innate immune response, sensing and responding to intracellular bacteria and DNA viruses by initiating transcription into dsRNA, which then activates the RIG-I pathway.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerase III subunit RPC9 could open doors to potential therapeutic strategies, particularly in enhancing innate immune responses and modulating CGRP responsiveness in various tissues.